Lindbrook Capital’s Cogent Biosciences COGT Stock Holding History

Lindbrook Capital’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$1.97K	Buy	329 +60	+22%	+$470	﹤0.01%	2290
2024 Q4	$2.1K	Hold	269	–	–	﹤0.01%	2291
2024 Q3	$2.9K	Sell	269 -107	-28%	-$1.04K	﹤0.01%	2232
2024 Q2	$3.17K	Buy	+376	New	+$2.85K	﹤0.01%	2195
2023 Q4	–	Sell	-271	Closed	-$2.64K	–	2714
2023 Q3	$2.64K	Buy	271 +63	+30%	+$747	﹤0.01%	2024
2023 Q2	$2.46K	Hold	208	–	–	﹤0.01%	2069
2023 Q1	$2.24K	Sell	208 -151	-42%	-$1.93K	﹤0.01%	2197
2022 Q4	$4.15K	Hold	359	–	–	﹤0.01%	1916
2022 Q3	$5K	Buy	+359	New	+$4.92K	﹤0.01%	1645

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Lindbrook Capital's COGT Position: Q1 2025 in Review

Lindbrook Capital increased its Cogent Biosciences (COGT) stake by 22% in Q1 2025, buying an estimated $470 and bringing the position to 329 shares worth $1.97K. The position accounts for ﹤0.01% of the portfolio, ranked #2290.

Lindbrook Capital first reported a position in COGT in Q3 2022 and has held it in 9 quarters since. The position peaked at $5K in Q3 2022. 186 funds tracked by Wall St. Rank hold COGT as of Q1 2025.

Lindbrook Capital held 329 shares of Cogent Biosciences worth $1.97K as of Q1 2025.
Lindbrook Capital bought 60 Cogent Biosciences shares in Q1 2025, an estimated $470.
Cogent Biosciences made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2290 holding.
Lindbrook Capital first reported a position in Cogent Biosciences in Q3 2022 and has held it in 9 quarters since.
Lindbrook Capital's Cogent Biosciences position peaked at $5K in Q3 2022.
186 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.